IAS 2013: Many People Need Hepatitis B Treatment in the Gambia
- Details
- Category: HBV Treatment
- Published on Monday, 15 July 2013 00:00
- Written by Liz Highleyman
About 8% of people tested through a community-based screening program in the Gambia have hepatitis B, and about 8% of these have advanced liver disease and meet European criteria for antiviral therapy, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.
IAS 2013: Kidney Problems Linked to Tenofovir Use, Improve with Switch to Abacavir
- Details
- Category: Liver, Kidney & Bone Toxicity
- Published on Monday, 15 July 2013 00:00
- Written by Liz Highleyman
Indian people with HIV who took tenofovir had a higher rate of kidney impairment than westerners, according to a study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur. A related study found that switching from tenofovir to abacavir reduced kidney risk.
IAS 2013: FibroScan Predicts Liver Decompensation and Death Among HIV/HCV Coinfected People
- Details
- Category: HCV Disease Progression
- Published on Monday, 08 July 2013 00:00
- Written by Liz Highleyman
The non-invasive transient elastometry method of estimating liver damage may be a better way to predict which people coinfected with HIV and hepatitis C will progress to decompensated liver cirrhosis and death, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013).
IAS 2013: Genetic Testing Lowers Risk of Nevirapine Skin Rash
- Details
- Category: Side Effects - HIV
- Published on Monday, 15 July 2013 00:00
- Written by Liz Highleyman
Screening for genetic mutations could substantially reduce the risk of hypersensitivity reactions involving skin rash among people starting nevirapine, according to a late-breaker report at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.
IAS 2013: Second-line Therapy in Resource-limited Settings [VIDEO]
- Details
- Category: HIV Treatment
- Published on Monday, 08 July 2013 00:00
- Written by Gregory Fowler
A second-line regimen of a protease inhibitor plus either 2 NRTIs or raltegravir (Isentress) led to good outcomes for people with HIV in Africa after initial regimen failure, according to a study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
More Articles...
- IAS 2013: Lower-dose Efavirenz as Effective as Standard Dose [VIDEO]
- IAS 2013: Early Testing and Treatment Linked to Lower Sexual Risk in Thai Study [VIDEO]
- IAS 2013: Studies Look at Second-Line Bone Changes, Fractures, and HIV- and HCV-Related Bone Loss
- IAS 2013: No Increase in Risk Behavior among People Taking ART, Meta-Analysis Shows
Web Design and Development by